CVS Health (CVS) Rebounds +12% in Last 30 Days: Key Drivers and Performance Insights
Key Takeaways
- CVS Health stock rose approximately +12% over the last 30 days, rebounding from late-March lows around $70 amid positive market sentiment and sector outperformance.
- Over the past quarter, shares gained +12%, supported by a strong Q4 2025 earnings beat despite intra-quarter volatility.
- Key drivers include robust Q4 revenue growth to a record $105.7 billion and adjusted EPS of $1.09, exceeding estimates.
- Broader influences encompass health insurance segment pressures balanced by pharmacy services strength and positive analyst attention.
- Stock exhibited volatile but upward-trending movement, outperforming the medical sector in recent periods.
CVS Health (CVS) Company Overview and Market Position
CVS Health Corporation (CVS) stands as a diversified healthcare company operating one of the largest pharmacy retail chains in the United States, with over 9,000 locations that provide prescription drugs, health products, and MinuteClinic walk-in services. Its business spans three core segments: Health Care Benefits through Aetna for health insurance plans, Pharmacy Services for pharmacy benefit management (PBM) that processes prescriptions for clients, and the Consumer segment covering retail pharmacies and front-store sales. In my view, CVS holds a strong position in both retail pharmacy and PBM spaces, going up against competitors like Walgreens Boots Alliance (WBA) and UnitedHealth Group (UNH). The integrated model—blending retail, PBM, and insurance—offers resilience to challenges like reimbursement pressures, though it also carries regulatory risks in Medicare Advantage plans, which helps explain some of the recent price volatility linked to earnings cost visibility.
CVS Health (CVS) Stock Price Performance: 30 Days vs. Quarter
Over the last 30 days, CVS stock has advanced +12%, moving from around $70 to a recent close near $78. The path has been volatile but clearly upward-trending, with a notable rebound kicking off in early April from $73, hitting highs close to $79, and then settling in the $77-$78 range.
Looking at the past quarter, shares delivered a +12% gain, recovering from mid-January levels near $74. There were early peaks above $83, a mid-quarter pullback to the low $70s, and solid recent strength. The performance stayed range-bound at points but trended higher overall, in line with healthcare market movements.
Key Factors Behind CVS Stock's 30-Day Rise
The +12% gain in the last 30 days reflects renewed investor confidence after a March dip, as CVS outperformed the medical sector's decline. I also checked recent sessions with Tickeron’s AI Trend Prediction Engine, which highlighted consistent gains like a 3.32% intraday move amid broader market advances where CVS often exceeded benchmarks. Analyst coverage has turned more positive, noting the stock's upward momentum—such as a 4.2% climb in early April that beat the sector's 4.81% loss. Resilience in pharmacy and benefits segments, along with stabilizing healthcare demand, drove the rebound. Without major earnings or M&A events, the lift came from sustained operational strength from earlier quarters.
Quarterly Performance Drivers for CVS Stock
The quarter's +12% increase was driven primarily by CVS Health's Q4 2025 earnings on February 10, 2026, where adjusted EPS reached $1.09—beating consensus estimates of $1.00 by 9%—and revenue hit $105.7 billion, topping forecasts by 2% with 8% year-over-year growth. Full-year 2025 revenue also marked a record at $402.1 billion, up 7.8%. These figures demonstrated efficiency in pharmacy services and health benefits, even with Medicare cost pressures. Volatility stemmed from a January drop after guidance review and a March pullback amid valuation worries and sector shifts. Institutional buying and beats against the S&P 500 in key sessions boosted returns. Broader supports included healthcare spending trends and PBM regulatory stability, with CVS's integrated care positioning helping offset headwinds.
Trending AI Robots: A Tool I Use for Smarter Trading
In my analysis and trading routine, I often turn to Tickeron’s Trending AI Robots page, which spotlights the best-performing AI trading bots from a library of hundreds of algorithms trading thousands of tickers across markets. It curates bots excelling lately based on current conditions and strategies like momentum, mean reversion, or pattern recognition for short-term, swing, or long-term plays. Metrics such as win rate, average return, and Sharpe ratio give clear performance views. Whether for scalping or trend following, this resource provides transparent live insights that have helped refine my approach.
CVS Stock Outlook: What to Watch Moving Forward
From what I see, investors should keep an eye on Q1 2026 earnings for insights into Medicare Advantage enrollment, PBM pricing, and Health Care Benefits margins. Watch for retail pharmacy consolidation, telehealth growth, and shifts in competitive landscape. Macro elements like interest rates, inflation on consumer spending, and policy changes in healthcare will matter. Potential upsides lie in cost controls, Aetna membership expansion, and MinuteClinic usage, while risks include PBM regulatory probes or drug pricing reforms—this is something I’m watching closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for CVS turns positive, indicating new upward trend
CVS saw its Momentum Indicator move above the 0 level on April 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
CVS moved above its 50-day moving average on April 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on April 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 234 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CVS broke above its upper Bollinger Band on May 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.519) is normal, around the industry mean (3.745). P/E Ratio (40.447) is within average values for comparable stocks, (39.152). CVS's Projected Growth (PEG Ratio) (0.269) is slightly lower than the industry average of (1.184). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.021). P/S Ratio (0.288) is also within normal values, averaging (0.676).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. CVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement